BCM
LUCD icon

Bridgeway Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Bridgeway Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-135,000
Closed -$190K – 1345
2023
Q4 		$190K Hold
135,000
– – ﹤0.01% 1147
2023
Q3 		$158K Hold
135,000
– – ﹤0.01% 1136
2023
Q2 		$188K Hold
135,000
– – ﹤0.01% 1146
2023
Q1 		$189K Hold
135,000
– – 0.01% 1116
2022
Q4 		$184K Sell
135,000
-50,000
-27% -$90K ﹤0.01% 1102
2022
Q3 		$283K Hold
185,000
– – 0.01% 1063
2022
Q2 		$418K Hold
185,000
– – 0.01% 924
2022
Q1 		$622K Buy
+185,000
New +$676K 0.01% 888

Other funds holding LUCD

LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bridgeway Capital Management's LUCD Position: Q1 2024 in Review

Bridgeway Capital Management sold out of Lucid Diagnostics (LUCD) in Q1 2024, closing a stake of 135,000 shares — an estimated $190K sold.

Bridgeway Capital Management first reported a position in LUCD in Q1 2022 and held it in 8 quarters. The position peaked at $622K in Q1 2022. 30 funds tracked by Wall St. Rank hold LUCD as of Q1 2024.

  • Bridgeway Capital Management reported no remaining Lucid Diagnostics position as of Q1 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 135,000 Lucid Diagnostics shares in Q1 2024, an estimated $190K.
  • Bridgeway Capital Management first reported a position in Lucid Diagnostics in Q1 2022 and held it in 8 quarters.
  • Bridgeway Capital Management's Lucid Diagnostics position peaked at $622K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2024.

Based on Bridgeway Capital Management's 13F filing for Q1 2024, filed 15 May 2024.